Single use Bioreactors Market

The single-use bioreactors market is projected to reach USD 9.58 billion by 2031 from an estimated USD 5.43 billion in 2026, at a CAGR of 12.0% during the forecast period. Market growth is driven by expanding biologics and biosimilar production, increasing outsourcing to CDMOs, and the rising adoption of flexible manufacturing technologies for monoclonal antibodies, vaccines, recombinant proteins, viral vectors, and cell & gene therapies. The transition toward modular facilities, intensified processing, and closed manufacturing workflows is further accelerating demand for single-use bioreactor systems, bags, assemblies, sensors, and supporting fluid-management components.

The global single-use bioreactors market is relatively consolidated, with Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany) collectively accounting for a substantial majority of the market. These companies have adopted strategies such as product launches, acquisitions, technology collaborations, manufacturing capacity expansions, and geographic investments to strengthen their positions. Competition centers on scalable bioreactor platforms, recurring consumables, perfusion compatibility, process automation, bag integrity, and integrated upstream processing solutions.

To know about the assumptions considered for the study download the pdf brochure

In April 2025, Thermo Fisher Scientific Inc. (US) introduced the 5 L DynaDrive Single-Use Bioreactor, extending the DynaDrive platform to benchtop process development and enabling more consistent scale-up from early development to commercial production.

In June 2025, Sartorius AG (Germany) completed the expansion of its Aubagne facility in France, nearly doubling its cleanroom space and adding automated production lines for 2D and 3D single-use bags to strengthen supply capacity for biopharmaceutical manufacturing.

Sartorius AG (Germany)

Sartorius AG (Germany) is a leading provider in the single-use bioreactors market, offering an extensive portfolio of bioreactors, consumables, fluid management solutions, filtration systems, process analytics, and automation platforms. Its single-use bioreactor portfolio includes Ambr high-throughput systems, Biostat RM rocking-motion systems, and Biostat STR stirred-tank bioreactors with Flexsafe bags for process development through commercial manufacturing. The company’s strong market position is supported by its broad installed base, scalable product architecture, recurring consumables business, and ability to integrate upstream processing with filtration, fluid management, and analytical technologies. Its recent strategies have focused on capacity expansion, process intensification, automation, and supply-chain resilience. In June 2025, Sartorius completed the expansion of its Aubagne facility in France, nearly doubling cleanroom space and adding automated production lines for 2D and 3D single-use bags.

Danaher Corporation (US)

Danaher Corporation (US), through Cytiva and Pall Corporation, holds a prominent position in the single-use bioreactors market. Cytiva offers Xcellerex X-platform and XDR stirred-tank bioreactors, WAVE rocking bioreactors, single-use mixers, cell-retention technologies, sensors, automation systems, and associated bags and assemblies. Pall complements this portfolio with Allegro bioreactors, fluid-management systems, filtration products, and supporting single-use components. Danaher benefits from an integrated bioprocessing portfolio, an extensive global service network, established customer relationships, and capabilities spanning upstream processing, clarification, filtration, and purification. The company has focused on product innovation, process intensification, digital integration, collaborations, and regional capability expansion. In March 2025, Cytiva expanded the Xcellerex X-platform with 500 L and 2,000 L configurations, enabling scale-up from 50 L to 2,000 L across batch, fed-batch, and perfusion processes.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific Inc. (US) is a major supplier of single-use bioreactor systems and integrated bioproduction technologies. Its portfolio includes DynaDrive and HyPerforma single-use bioreactors, BioProcess containers, films, fluid-transfer assemblies, controllers, sensors, and filtration technologies. The DynaDrive platform supports consistent scale-up from benchtop process development to large-scale commercial manufacturing, while the company’s broader offering enables customers to integrate media preparation, cell culture, harvesting, purification, and analytical workflows. Its market position is supported by a global manufacturing and distribution network, broad customer access, and extensive technical and process-development capabilities. In April 2026, the company opened a flagship US Bioprocess Design Center in Plainville, Massachusetts, to support process optimization, technology evaluation, and scale-up.

Merck KGaA (Germany)

Merck KGaA (Germany) is an established provider of single-use bioreactors and integrated bioprocessing solutions through its Life Science business. Its portfolio includes Mobius stirred-tank bioreactors from benchtop to commercial scale, Mobius iFlex systems for intensified and perfusion processing, Mobius Breez microbioreactors, Cellicon cell-retention technologies, Flexware assemblies, single-use process containers, and filtration products, among others. The company combines bioreactor hardware, consumables, media, fluid management, and downstream technologies to support monoclonal antibody, recombinant protein, vaccine, and viral-vector manufacturing. Its competitive position is strengthened by its broad Process Solutions portfolio, global customer collaboration centers and established presence across major biomanufacturing regions.

Market Ranking

The single-use bioreactors market is consolidated, with Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany) collectively estimated to account for 70–75% of the global market in 2025. Sartorius holds a leading position due to its broad portfolio spanning Ambr process-development systems, Biostat RM and STR bioreactors, Flexsafe bags, automation, and fluid-management technologies. Danaher, through Cytiva and Pall Corporation, benefits from its Xcellerex and Allegro platforms, extensive filtration capabilities, and integrated upstream-to-downstream bioprocessing portfolio. Thermo Fisher maintains a strong position through its scalable DynaDrive and HyPerforma systems, proprietary single-use containers, and global bioprocess design-center network. Merck competes through its Mobius bioreactor family, perfusion-ready iFlex platform, Flexware assemblies, cell-retention systems, media, and filtration solutions.

The remaining 25–30% is shared among Getinge AB (Sweden), Eppendorf SE (Germany), ABEC, Inc. (US), PBS Biotech, Inc. (US), Distek, Inc. (US), Tofflon Life Science Co., Ltd. (China), and other specialized suppliers. Competition is driven by scalability, mixing and oxygen-transfer performance, bag integrity, perfusion compatibility, automation, supply reliability, technical support, and total operating cost. Specialized companies continue to compete effectively in vertical-wheel, fixed-bed, rocking-motion, microbial, and advanced therapy-specific bioreactor technologies.

Related Reports:

Single-Use Bioreactors Market by Product [System (By Scale), Bags (2D, 3D), Assemblies], Type (Stirred Tank), Cell Type (Mammalian, Bacterial, Yeast), Molecule (mAbs, Vaccines, CGT), Process Mode, Application, Competition, Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]